European synthetic biology company Octarine receives funding to develop biosynthetic platform for cannabinoid and psilocybin derivatives
COPENHAGEN, Denmark–(BUSINESS WIRE)–Today, Octarine Bio IVS (“Octarine” or the “Company”), a synthetic biology company developing functionally superior cannabinoid and psilocybin derivatives using microbial fermentation announce a successful fundraising from private investors including Oskare Capital and Canopy Growth Cooperation (“Canopy Growth”) former CEO and founder Bruce Linton. Canopy Growth was the first cannabis producing company in…
Details